Psilocybe cubensis

Traditional and historical use

Archaeological evidence places ceremonial psilocybin mushroom use in Mesoamerica at least 3,000–3,500 years in the past, based on mushroom-shaped stone effigies from Guatemala and southern Mexico dating from around 1000 BCE to 900 CE.^[3] The Mazatec people of Oaxaca used psilocybin mushrooms — called teonanácatl ("flesh of the gods" in Nahuatl) — in the Velada, a nocturnal healing ceremony guided by a curandera. Scholarly documentation of indigenous practices spans anthropology, archaeology, ethnolinguistics, and ethnomycology.^[9]

Western discovery and research

R. Gordon Wasson participated in a Mazatec Velada ceremony with the curandera María Sabina in 1955 and published his account in Life magazine in 1957 — the first major Western public exposure to psilocybin mushrooms.^[10] Roger Heim collected and identified the specimens; Albert Hofmann at Sandoz Laboratories isolated psilocybin and psilocin in 1958.^[4]

Modern era

Psilocybin was classified as Schedule I in the US in 1970, and the 1971 UN Convention listed psilocybin and psilocin — though the mushrooms themselves were not explicitly named.^[11] Research effectively halted for three decades until a 2006 Johns Hopkins trial showed psilocybin reliably occasioned meaningful mystical-type experiences, with 67% of volunteers rating the session among their five most personally meaningful life experiences.^[5] Subsequent milestones include FDA Breakthrough Therapy designations for depression, Oregon's regulated psilocybin services framework (first centres opened 2023), and Australia's rescheduling to permit psychiatric prescribing.^[12]

Psilocybe cubensis (Earle) Singer belongs to the family Hymenogastraceae. First described as Stropharia cubensis by Franklin Sumner Earle in 1906 from Cuban specimens,^[13] it was transferred to Psilocybe by Rolf Singer in 1949. Gastón Guzmán's 1983 monograph on the genus remains the authoritative taxonomic treatment.^[14]

P. cubensis is a subtropical-to-tropical species found naturally across Central America, South America, Southeast Asia, and northern Australia, typically fruiting from cattle or horse dung in warm, humid pastures. It is the most widely cultivated psilocybin mushroom, growing vigorously on simple substrates and tolerating variable conditions.

The mature cap is convex to broadly umbonate, 2–8 cm across, ranging from pale golden to caramel brown with a darker centre. The stipe is whitish and bruises blue-green when damaged — the hallmark bluing reaction of psilocybin-containing tissue. The critical identification risk for wild foragers is confusion with Galerina marginata, which contains lethal amatoxins.^[15] The most reliable discriminators are spore print colour (purplish-black for Psilocybe, rusty-brown for Galerina) and the bluing reaction. Fruiting bodies are typically dried for storage; 1 g dried corresponds to roughly 10 g fresh.

The dominant psychoactive compound in P. cubensis is psilocybin — a tryptamine prodrug rapidly converted in the body to psilocin by alkaline phosphatases.^[16] Psilocin is the active molecule, acting primarily on serotonin receptors in the prefrontal cortex.^[2] Dried fruiting bodies typically contain 0.5–1.0% psilocybin and 0.1–0.3% psilocin by dry weight, though concentrations vary widely across specimens.

The mushroom also contains β-carboline alkaloids that inhibit MAO-A (MAO-A) — an enzyme involved in breaking down psilocin.^[17] These β-carbolines may extend psilocin's effects in whole-mushroom preparations compared to synthetic psilocybin, though this has not been confirmed in human studies.^[18] Minor alkaloids — baeocystin, norbaeocystin, and aeruginascin — are present at lower concentrations; their individual contributions to the experience are poorly understood. Psilocybin's oral bioavailability is approximately 52.7%, peaking in the bloodstream 1.8–4 hours after ingestion.^[19]

Alkaloid content varies 2–4-fold across individual fruiting bodies even within a single cultivation batch.^[8] Growing conditions, substrate composition, harvest timing, and cultivar all influence potency. This variability is the primary obstacle to accurate dose prediction with uncharacterised mushroom material.

Where it acts

Psilocin crosses the blood-brain barrier and activates serotonin receptors concentrated in pyramidal neurons of the prefrontal cortex — the primary mechanism underlying psychedelic effects.^[2] It also engages serotonin receptors linked to calming inhibitory signals,^[20] and activates a receptor that promotes neuroplasticity — changes in brain connectivity that may persist well beyond the acute experience.^[2]

What it changes

The REBUS model proposes that psilocin loosens the brain's top-down predictions, letting raw sensory input drive experience more strongly and increasing the variability of brain signals.^[21] A single 25 mg dose disrupted brain functional connectivity more than threefold compared to methylphenidate in precision brain imaging, with the strongest effects in the default mode network — the system linked to self-referential thought. A decrease in one key connectivity measure persisted for three weeks after the session.^[22]

Wild foraging carries risk of fatal misidentification with Galerina marginata, which contains lethal amatoxins.^[15] Products sold as psilocybin may be adulterated — NBOMe-series compounds have been detected in pressed tablets and powders. Ehrlich reagent testing confirms indole presence but cannot identify all synthetic imposters; definitive identification requires GC-MS or LC-MS/MS.^[26] Cultivated mushrooms are susceptible to mould contamination.safety citation needed

Persisting psychosis is rare but documented, primarily in people with a personal or family history of psychotic disorders.^[7]

Persistent visual disturbances — geometry, halos, trails, and visual haze / noise — can continue after use ceases, a condition known as HPPD (HPPD).^[27] HPPD has been documented in adolescents^[28] and adults; precise prevalence estimates remain unavailable.

Psilocybin produces no physical dependence and no clinically recognised withdrawal syndrome.^[7][29] A systematic review of psilocybin for substance use disorders found no addiction signals.^[30]

SSRIs: Long-term SSRI use blunts subjective psychedelic effects. No serotonin syndrome cases from SSRI + psilocybin have been documented in the peer-reviewed literature.^[32]

Lithium: Potentially hazardous; proposed mechanisms include serotonergic amplification and pro-convulsant effects.^[7]safety citation needed

Cannabis: May add to anxiety and paranoia and intensify subjective effects. No specific pharmacokinetic interaction is documented.

CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine): may prolong psilocin exposure by impairing its primary metabolic pathway.^[16]

Contraindications

Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.

Psilocybin and psilocin are scheduled under the 1971 UN Convention on Psychotropic Substances — though psilocybin mushrooms themselves were not explicitly named in the treaty.^[11] This ambiguity has allowed some jurisdictions to permit whole-mushroom or truffle use while formally prohibiting the isolated compounds. In the United States, psilocybin and psilocin are Schedule I under federal law, with a rescheduling petition pending as of 2025; Oregon operates a regulated therapeutic access framework (first centres opened 2023); Colorado has decriminalised personal use for adults; and several cities — including Oakland, Santa Cruz, Ann Arbor, and Seattle — have passed local deprioritisation measures.^[11] In the United Kingdom, psilocybin is Class A — the most severe penalty category.^[11] Australia rescheduled psilocybin in 2023 to permit prescribing by authorised psychiatrists for treatment-resistant depression.^[12] The Netherlands prohibits dried mushrooms but permits psilocybin-containing truffles; Canada permits access via exemption for palliative care and therapist training. The legal landscape is shifting rapidly across many jurisdictions.